IL17A and COVID-19: Attenuating the NLRP3 inflammasome pathway by VitD3 was accompanied by a decrease in IL-1β, IL-6, IL-17, and D-dimer, reduced hyperinflammation of severely infected COVID-19 patients, as well as correlated with enhanced type I IFN signaling and reduced disease severity.